JAK2(V617F)-negative ET Patients do not display constitutively active JAK/STAT signaling

OBJECTIVE: Presence of the JAK2(V617F) mutation in only 40-60% of patients with Essential Thrombocythemia (ET) underscores the heterogeneity of this myeloproliferative disorder (MPD). Several distinct mutations, either in JAK2 (exon 12) or in c-Mpl (W515L) have been described in subsets of other MPD...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Schwemmers, Sven, Will, Britta, Waller, Cornelius F., Abdulkarim, Khadija, Johansson, Peter, Andreasson, Björn, Pahl, Heike L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2007
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2270411/
https://ncbi.nlm.nih.gov/pubmed/17764814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.exphem.2007.07.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak